| First Author | Koehm S | Year | 2007 |
| Journal | J Allergy Clin Immunol | Volume | 120 |
| Issue | 3 | Pages | 570-7 |
| PubMed ID | 17561243 | Mgi Jnum | J:286324 |
| Mgi Id | MGI:6403050 | Doi | 10.1016/j.jaci.2007.04.037 |
| Citation | Koehm S, et al. (2007) HLA-DRB1 alleles control allergic bronchopulmonary aspergillosis-like pulmonary responses in humanized transgenic mice. J Allergy Clin Immunol 120(3):570-7 |
| abstractText | BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a lung hypersensitivity disease mediated in part by CD4(+) T(H)2 cells. There is a significant association between ABPA and the HLA-DR2 genotypes DRB1(*)1501 and DRB1(*)1503, whereas resistance might be associated with HLA-DRB1(*)1502. OBJECTIVE: We sought to elucidate the role of HLA-DR alleles in allergic inflammation in lungs. METHODS: HLA-DR humanized transgenic mice expressing either the susceptible or resistant alleles were analyzed for the nature and extent of pulmonary inflammation after exposure to Aspergillus species antigens. RESULTS: Exposed DRB1(*)1501 and DRB1(*)1503 transgenic mice displayed infiltrates made up prominently of eosinophils, which is consistent with the inflammation found in ABPA. The resistant DRB1(*)1502 mice, on the other hand, displayed minimal to moderate inflammation, consisting mainly of T-cell infiltrates. Significantly more mucin was produced in the DRB1(*)1503 and DRB1(*)1501 mice, and their ability to limit the number of Aspergillus species conidia within the lung parenchyma was impaired. Despite their differences, both the DRB1(*)1503 and DRB1(*)1502 strains mounted comparable T cell-proliferative responses to Aspergillus species antigens. CONCLUSION: The HLA-DR2 alleles DRB1(*)1501 and DRB1(*)1503 play a major role in the development of allergic pulmonary inflammation. In contrast, the HLA-DR2 allele DRB1(*)1502 mediates a nonallergic T(H)1-like response to the organism, possibly explaining an ABPA resistance factor. These results are in support of our published human studies in patients with cystic fibrosis and asthma. CLINICAL IMPLICATIONS: HLA-DR typing in patients with cystic fibrosis and asthma will aid in the identification of individuals at risk for ABPA. |
